Found 168 clinical trials
-
Multi-country trial
-
Phase 2 trial
-
Accepting Seniors
-
Accepting adults
-
Pediatrics/Neonatology
-
Currently Recruiting
An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis
The purpose of this study is to evaluate the efficacy and safety of itacitinib combined with low-dose ruxolitinib or itacitinib alone in subjects with myelofibrosis. This is an open-label Phase 2 study with 2 cohorts: Cohort A: Itacitinib plus ruxolitinib Drug: Itacitinib self-administered orally once daily at the protocol-defined …
- 141 views
- 14 Dec, 2020
- 11 locations
-
Unknown Phase
-
Accepting pediatric ages
-
Currently Recruiting
AAML08B1: Biology Study of Transient Myeloproliferative Disorder (TMD) in Children with Down Syndrome (DS)
AAML08B1: Biology Study of Transient Myeloproliferative Disorder (TMD) in Children with Down Syndrome (DS)
- 118 views
- 08 Nov, 2020
- 1 location
-
Unknown Phase
-
Accepting pediatric ages
-
Currently Recruiting
AAML08B1: Biology Study of Transient Myeloproliferative Disorder (TMD) in Children With Down Syndrome (DS)
AAML08B1: Biology Study of Transient Myeloproliferative Disorder (TMD) in Children With Down Syndrome (DS)
- 368 views
- 08 Nov, 2020
- 1 location
-
Phase 1 trial
-
Accepting Seniors
-
Accepting adults
-
Musculoskeletal
-
Currently Recruiting
A Phase 1/2 Open-Label, Multicenter Study of INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Anemia Due to Myeloproliferative Disorders
, and determining its antianemic activity when combined with ruxolitinib in participants with transfusion-dependent or symptomatic anemia due to myeloproliferative disorders.
- 67 views
- 05 Oct, 2020
- 1 location
-
Multi-country trial
-
Phase 2 trial
-
Accepting Seniors
-
Accepting adults
-
10s of participants
-
An interventional trial
-
For all genders
-
Currently Recruiting
A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement - (FIGHT-203)
The purpose of this study is to evaluate the efficacy and safety of pemigatinib (INCB054828) in subjects with myeloid/lymphoid neoplasms with fibroblast growth factor receptor (FGFR) 1 rearrangement.
- 272 views
- 24 Dec, 2020
- 76 locations
-
Multi-country trial
-
Phase 3 trial
-
Accepting pediatric ages
-
Accepting Seniors
-
100s of participants
-
An interventional trial
-
For all genders
-
Currently Recruiting
Vedolizumab in the Prophylaxis of Intestinal Acute Graft Versus Host Disease (aGVHD) in Participants Undergoing Allogeneic Hematopoietic Stem Cell (Allo-HSCT) Transplantation
aGvHD-free survival by Day +180 in participants who receive allo-HSCT as treatment for a hematologic malignancy or myeloproliferative disorder.
- 42 views
- 28 Oct, 2020
- 113 locations
-
Multi-country trial
-
Phase 2 trial
-
Accepting Seniors
-
Accepting adults
-
100s of participants
-
An interventional trial
-
For all genders
-
Currently Recruiting
Carfilzomib Thalidomide and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma
known to induce genetic instability and in turn gives rise to secondary cancers. In combination with lenalidomide (25mg), Niesvizky and colleagues have demonstrated a maximum planned dose (MPD) of
- 22 views
- 21 Jan, 2021
- 1 location
-
Multi-country trial
-
Phase 3 trial
-
Accepting Seniors
-
Accepting adults
-
100s of participants
-
An interventional trial
-
For all genders
-
Currently Recruiting
Ropeginterferon Alfa-2b (P1101) vs. Anagrelide in Essential Thrombocythemia Patients With Hydroxyurea Resistance or Intolerance
This is a Phase 3 open-label, multicenter, randomized, active-controlled study designed to compare the efficacy and safety and tolerability of P1101 compared with ANA after 12 months of treatment as second-line therapy for subjects with ET who have had a suboptimal or failed response to HU.
- 0 views
- 13 Jan, 2021
- 51 locations
-
Unknown Phase
-
Accepting Seniors
-
Accepting adults
-
1000s of participants
-
An interventional trial
-
For all genders
-
Endocrinology
-
Currently Recruiting
Health Impacts of a Climate Change Adaptation Strategy to Address Drinking-water Salinity in Coastal Bangladesh
Background (brief): Burden: Excessive salinity is common in groundwater aquifers across south-western coastal Bangladesh. Higher adult mean systolic and diastolic blood pressure and increased risk of gestational hypertension has been observed among those who drank tube-well water with high sodium content. 2. Knowledge gap: Managed Aquifer Recharge (MAR) systems, that …
- 4 views
- 08 Nov, 2020
- 1 location
-
Phase 1 trial
-
Accepting Seniors
-
Accepting adults
-
10s of participants
-
An interventional trial
-
For all genders
-
Currently Recruiting
A Study of TQ05105 Tablets in Subjects With Myeloproliferative Neoplasms
TQ05105 is a JAK2 inhibitors and can be used to treat JAK2 target-related diseases. The activation of the JAK/STAT pathway is related to abnormal proliferation, obstruction of apoptosis, and differentiation disorder of leukemia cells which is caused by genetic abnormalities and viral infection.
- 0 views
- 15 Apr, 2020
- 2 locations